Open AccessFecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease
Author(s) -
Michael Wagner,
Christer Peterson,
Peter Ridefelt,
Per Sangfelt,
Marie Carlson
Publication year - 2008
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.14.5584
Subject(s) - calprotectin , inflammatory bowel disease , medicine , gastroenterology , ulcerative colitis , myeloperoxidase , surrogate endpoint , immunology , feces , crohn's disease , disease , inflammation , biology , paleontology
To evaluate fecal calprotectin (FC) as a surrogate marker of treatment outcome of relapse of inflammatory bowel disease (IBD) and, to compare FC with fecal myeloperoxidase (MPO) and fecal eosinophil protein X (EPX).